Therapeutic treatment with Ibrutinib attenuates imiquimod-induced psoriasis-like inflammation in mice through downregulation of oxidative and inflammatory mediators in neutrophils and dendritic cells

• Published in: European journal of pharmacology Vol. 877; p. 173088
• Main Authors: Al-Harbi, Naif O., Nadeem, Ahmed, Ahmad, Sheikh F., Bakheet, Saleh A., El-Sherbeeny, Ahmad M., Ibrahim, Khalid E., Alzahrani, Khalid S., Al-Harbi, Mohammed M., Mahmood, Hafiz M., Alqahtani, Faleh, Attia, Sabry M., Alotaibi, Moureq R.
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 15.06.2020
• Subjects: Adenine - analogs & derivatives; Adenine - pharmacology; Adenine - therapeutic use; Animals; Antioxidants; BALB 3T3 Cells; Bruton's tyrosine kinase; Dendritic Cells - drug effects; Dendritic Cells - metabolism; Down-Regulation - drug effects; Imiquimod - adverse effects; Inflammation Mediators - metabolism; Male; Mice; Neutrophils; Neutrophils - drug effects; Neutrophils - metabolism; Oxidation-Reduction - drug effects; Oxidative stress; Oxidative Stress - drug effects; Peroxidase - metabolism; Piperidines - pharmacology; Piperidines - therapeutic use; Psoriasis; Psoriasis - chemically induced; Psoriasis - drug therapy; Psoriasis - immunology; Psoriasis - metabolism; Signal Transduction - drug effects; Skin - drug effects; Skin - immunology; Skin - metabolism; Skin - pathology; Antioxidants; Oxidative stress; Psoriasis; Bruton's tyrosine kinase; Neutrophils
• ISSN: 0014-2999; 1879-0712
• DOI: 10.1016/j.ejphar.2020.173088

Psoriasis is clinically characterized by well-demarcated silvery plaques which may appear on the extremities, scalp, and sacral area. The multidimensional interactions among innate immune cells [neutrophils and dendritic cells (DCs)], adaptive immune cells and skin resident cells result in characteristic features of psoriatic inflammation such as acanthosis, hyperkeratosis, and parakeratosis. Tec family kinases are involved in the pathogenesis of several inflammatory diseases. One of them is Bruton’s tyrosine kinase (BTK) which is reported to carry out inflammatory and oxidative signaling in neutrophils and DCs. Effect of BTK inhibitor with regard to psoriatic inflammation has not been explored previously especially in a therapeutic setting. In the current investigation, effect of BTK inhibitor, Ibrutinib on oxidative/inflammatory signaling in dermal/splenic neutrophils [phosphorylated BTK (p-BTK), inducible nitric oxide synthase (iNOS), nitrotyrosine], CD11c + DCs (p-BTK, iNOS, nitrotyrosine, MCP-1, TNF-α) and enzymatic antioxidants [superoxide dismutase (SOD), glutathione peroxidase (GPx), glutathione reductase (GR)] in imiquimod (IMQ)-induced psoriatic inflammation was evaluated using therapeutic mode. Our results show that IMQ treatment led to induction of p-BTK expression along with concomitant increase in oxidative stress in neutrophils, and CD11c + DCs in skin/periphery. Therapeutic treatment with Ibrutinib caused attenuation of IMQ-induced oxidative stress in CD11c + DCs and neutrophils. Further there were dysregulations in antioxidants enzymes (SOD/GPx/GR) in the skin of IMQ-treated mice, which were corrected by Ibrutinib. In short, our study reveals that BTK signaling in neutrophils and CD11c + DCs upregulates oxidative stress which is concomitant with psoriatic inflammation in mice. Ibrutinib attenuates psoriasis inflammation through downregulation of oxidative stress in these innate immune cells.